Browsing by Author "Ferres Garrido, Marcela Viviana"
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- ItemA simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR(2020) Wozniak Banchero, Aniela; Cerda Rojas, Ariel Patricio; Lamig Giannini, Liliana Andrea; Solari Gajardo, Sandra; Guzmán Durán, Ana María; Riveras Hernández, Eleodoro Javier; Ferres Garrido, Marcela Viviana; Gutiérrez Ilabaca, Rodrigo Antonio; García Cañete, Patricia; Ibarra Henriquez, C.; Sebastian, V.; Armijo, G.; Lamig, L.; Miranda, C.; Lagos, M.; Quiroga, T.; Hitschfeld, S.
- ItemAporte de la biología molecular en el diagnóstico de infecciones respiratorias agudas(2016) Budnik Ojeda, Isolda Cecilia; Ferres Garrido, Marcela Viviana; Pardo Tarrago, Trinidad; Edwards Tagle, Javiera; Labarca Trucios, Gonzalo Patricio; Reyes Zaldivar, Felipe Tomas; Martínez Valdebenito, Constanza Pamela; Montecinos Perret, Luisa Paola; Perret Pérez, Cecilia
- ItemClinical and epidemiological manifestations of parainfluenza infection in hospitalized children(SOC CHILENA INFECTOLOGIA, 2007) Vega Briceño, Luis Enrique; Pulgar B., Dahiana; Potin Santander, Marcela Patricia; Ferres Garrido, Marcela Viviana; Sánchez Díaz, Ignacio
- ItemClinical characterizes of respiratory infection due to Mycoplasma pneumoniae in hospitalized children(SOC CHILENA INFECTOLOGIA, 2009) Paul Delfau, María de los Ángeles; Vega Briceño, Luis Enrique; Potin Santander, Marcela Patricia; Ferres Garrido, Marcela Viviana; Pulgar B., Dahiana; García Bruce, Cristián Jorge; Holmgren Palmen, Nils Linus Anders; Sánchez Díaz, Ignacio
- ItemConsenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Parte II: Guía clínica chilena de Prevención de Infecciones Asociadas al Uso de Terapias Biológicas (PREVITEB)(2019) Cerón Araya, Inés María; Vizcaya Altamirano, María Cecilia; Gambra, Pilar; Ferres Garrido, Marcela Viviana; Bidart, Teresa; Lépez Quizhpi,Tania Lorena; Acuña, María Paz; Álvarez, Ana María; Zubieta, Marcela; Durán, Luisa; Rabagliati Borie, Ricardo MiguelThe use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of 2 manuscripts. This second part is a guideline that details these recommendations through screening strategies, prophylactic therapies and vaccines indications for bacterial, mycobacterial, viral, fungal and parasitic infections, both for adults and children.
- ItemHuman metapneumovirus as hospitalization cause in children under 3 years old with acute respiratory infections during 2004,Metapneumovirus humano como causa de hospitalización en niños bajo 3 años de edad, con infección respiratoria aguda, durante el año 2004(2007) Prado Sanhueza, Maria Alejandra; Perret Pérez, Cecilia; Montecinos Perret, Luisa Paola; Veloz B., A.; Le Corre Pérez, Monique Nicole; Habash A., L.; Potin Santander, Marcela Patricia; Abarca Villaseca, Katia; Ferres Garrido, Marcela VivianaMetapneumovirus humano (MPVh) fue detectado entre julio y noviembre en 15 de 123 niños bajo 3 años de edad hospitalizados por infección respiratoria aguda (12%). Las muestras fueron estudiadas mediante técnicas de biología molecular (RPC-TR de muestra de hisopado nasofaríngeo y/o de sobrenadante de cultivo). El 67% de los niños hospitalizados con MPVh tenían menos de 1 año de edad, todos ellos presentaron tos y fiebre y el principal motivo de hospitalización fue el requerimiento de oxígeno en 73% de los casos. Si bien un tercio de los pacientes tenía patología previa, su evolución clínica no fue diferente respecto de los niños previamente sanos. El patrón radiológico mostró aumento de la trama intersticial, con focos de consolidación en 6 casos (40%). El diagnóstico más frecuente fue síndrome bronquial obstructivo o bronquiolitis, asociado o no a neumonía. Destaca la necesidad de un método de diagnóstico rápido para optimizar el diagnóstico diferencial, manejo y control de infecciones en estos pacientes.
- ItemInfection with SARS-CoV-2 variant Gamma (P.1) in Chile increased ICU admission risk three to five-fold(2023) Sauré, Denis; Rizzo, Alessandro; Neira, Ignasi; Goic, Marcel; O’Ryan, Miguel; Torres, Juan P.; Bruhn, Alejandro; Ferres Garrido, Marcela Viviana; Angulo Troncoso, Jenniffer Alexandra; Vera Alarcon, Maria Magdalena; Basso, Leonardo J.The 2021 wave of SARS-CoV-2 infection in Chile was characterized by an explosive increase in ICU admissions, which disproportionately affected individuals younger than 60 years. This second wave was also accompanied by an explosive increase in Gamma (P.1) variant detections and the massive vaccine rollout. We unveil the role the Gamma variant played in stressing the use of critical care, by developing and calibrating a queueing model that uses data on new onset cases and actual ICU occupancy, symptom’s onset to ICU admission interval, ICU length-of-stay, genomic surveillance, and vaccine effectiveness. Our model shows that infection with the Gamma (P.1) variant led to a 3.5–4.7-fold increase in ICU admission for people younger than 60 years. This situation occurred on top of the already reported higher infection rate of the Gamma variant. Importantly, our results also strongly suggest that the vaccines used in Chile (inactivated mostly, but also an mRNA), were able to curb Gamma variant ICU admission over infections.
- ItemReduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile(Oxford University Press for the Infectious Diseases Society of America, 2022) Balcells Marty, María Elvira; Le Corre Pérez, Monique Nicole; Durán Santa Cruz, Josefina Gracia; Ceballos Valdivielso, María Elena Andrea; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Dib Marambio, Martin Javier; Rabagliati Borie, Ricardo Miguel; Sarmiento Maldonado, Mauricio; Burgos Cañete, Paula Isabel; Espinoza Sepúlveda, Manuel Antonio; Ferres Garrido, Marcela Viviana; Martínez Valdebenito, Constanza Pamela; Ruiz-Tagle Seguel, Cinthya Grace; Ortiz Koh, Catalina Alejandra; Ross Pérez, Patricio Daniel; Budnik Bitran, Sigall; Solari Gajardo, Sandra; Vizcaya Vergara, María De Los Ángeles; Lembach, Hanns; Berríos Rojas, Roslye; Melo González, Felipe; Rios Raggio, Mariana; Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan Marcela; Nervi Nattero, BrunoBackground Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been widely implemented in low- and middle-income countries. However, immunogenicity in immunocompromised patients has not been established. Herein, we aimed to evaluate immune response to CoronaVac vaccine in these patients. Methods This prospective cohort study included 193 participants with 5 different immunocompromising conditions and 67 controls, receiving 2 doses of CoronaVac 8-12 weeks before enrollment. The study was conducted between May and August 2021, at Red de Salud UC-CHRISTUS, Santiago, Chile. Neutralizing antibody (NAb) positivity, total anti-SARS-CoV-2 immunoglobulin G antibody (TAb) concentrations, and T-cell responses were determined. Results NAb positivity and median neutralizing activity were 83.1% and 51.2% for the control group versus 20.6% and 5.7% (both P < .001) in the solid organ transplant group, 41.5% and 19.2% (both P < .0001) in the autoimmune rheumatic diseases group, 43.3% (P < .001) and 21.4% (PP = .001) in the cancer with solid tumors group, 45.5% and 28.7% (both P < .001) in the human immunodeficiency virus (HIV) infection group, 64.3% and 56.6% (both differences not significant) in the hematopoietic stem cell transplant group, respectively. TAb seropositivity was also lower for the solid organ transplant (20.6%; P < .0001), rheumatic diseases (61%; P < .001), and HIV groups (70.9%; P = .003), compared with the control group (92.3%). On the other hand, the number of interferon gamma spot-forming T cells specific for SARS-CoV-2 tended to be lower in all immunocompromising conditions but did not differ significantly between groups. Conclusions Diverse immunocompromising conditions markedly reduce the humoral response to CoronaVac vaccine. These findings suggest that a boosting vaccination strategy should be considered in these vulnerable patients.